Phase 2 N=23 sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Skin Kaposi Sarcoma
Primary: Proportion of Participants Experiencing Clinical Response — 56.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
Sarcoma
Primary: Proportion of Patients Who Achieve a Clinical Response — 0.33 proportion
Phase 2 N=19 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
Kaposi's Sarcoma · HIV Infections · HIV Seronegativity
Primary: Response Rate — 31 Percentage of participants
N/A N=357 Hemangioma Associated With High Rates of Morbidity
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Phase 2 N=10 Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2
Phase 2 N=36 RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
Phase 2 N=26 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
Human Immunodeficiency Virus 1 Positive · Skin Kaposi Sarcoma
Primary: Overall Response Rate — 0.577 proportion of participants
Phase 2 N=14 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi´s Sarcoma
Primary: Number of Participants With Complete Response — 1; 3 participants
N/A N=29 Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
Kaposi's Sarcoma
Primary: Preliminary Assessment of the Temperature of Kaposi's Sarcoma Lesions Compared to the Temperature in the Normal Skin Measured With Thermography — 1.1 Celsius
Phase 2 N=28 Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Kaposi Sarcoma · Sarcoma, Kaposi
Primary: Number of Participants With Grades 1-4 Adverse Events That Are Possibly, Probably, and/or Definitely Attributed to Pomalidomide — 21; 10; 1; 0 Participants
Phase 2 N=16 Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Sarcoma, Kaposi
Primary: Overall Response Rate (ORR) of Six Cycles of Liposomal Doxorubicin Combined With Bevacizumab in Patients With Advanced KS. — 50; 67 percentage of participants
Phase 2 N=30 Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 2 N=44 Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Locally Advanced Epithelioid Hemangioendothelioma · Metastatic Epithelioid Hemangioendothelioma · Unresectable Epithelioid Hemangioendothelioma
Primary: Objective Response Rate — 9.5 Percentage
N/A N=261 Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
Hemangioma
Primary: Frequency of Hepatic Hemangiomas Identified on Abdominal Ultrasound — 24 participants
Phase 2 N=5 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Kaposi's Sarcoma
Primary: Localization — 5 participants
Phase 2 N=16 Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Confirmed Response Rate (CR or PR) Using RECIST — 0 percentage of participants
Phase 2 N=41 Capecitabine and Temozolomide for Neuroendocrine Cancers
Neuroendocrine Tumors
Primary: Number of Participants With Partial Response (PR) — 9 participants
Phase 2 N=3 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
AIDS-Related Kaposi Sarcoma · Recurrent Kaposi Sarcoma
Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…
Phase 1 N=15 An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Kaposi Sarcoma · HIV Infections
Primary: To Determine the Safety of Escalating Doses of Tc 99m Tilmanocept in HIV Subjects With Biopsy-confirmed KS. — 0; 0; 0 Safety Signals
Phase 2 N=17 Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Pigmented Villonodular Synovitis · Diffuse-type Giant Cell Tumor · Tenosynovial Giant Cell Tumor
Primary: Percentage of Participants With Progression Free Survival — 82 percentage of participants with PFS
Phase 2 N=25 Defibrotide TMA Prophylaxis Pilot Trial
Thrombotic Microangiopathies
Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses
Phase 2 N=45 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
NF1 · Neurofibromatosis · Plexiform Neurofibromas
Primary: The Change in Tumor Size Based on Radiographic Assessment — -15.7; -4.1 mm^3
Phase 2 N=61 Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
Kaposiform Hemangioendotheliomas · Tufted Angioma · Capillary Venous Lymphatic Malformation
Primary: Overall Response by Radiologic Evaluation, Quality of Life Assessment, and Functional Impairment Score — 47; 7; 3 Participants
Phase 2 N=24 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Brain Cancer · Pediatric Cancers
Primary: Objective Response Rate — 0 Percentage of Participants
Phase 2 N=62 R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Neurofibroma, Plexiform · Neurofibromatosis Type I
Primary: Median Time to Progression — 10.6; 14.5; 19.2; 13.3 Months
N/A N=6 Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Sarcoma
Primary: Tumor Response Rate Every 4 Weeks — 4; 1 participants
Phase 1 N=18 Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
Peritoneal Surface Malignancy
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Early Phase 1 N=6 Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Neurofibromatosis · NF1 · Neurofibromas
Primary: Disease Response — 0; 0; 2; 1 Participants
Phase 1 N=8 Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Maximum Tolerable Dose (MTD) of Pazopanib — NA mg